Deepu Madduri

Hematology | Oncology

965 High St
Palo Alto, CA 94301

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

Journal: Nature medicine

Published: March 13, 2026

Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies.

Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 14, 2026

Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies.

Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 14, 2026

Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression.

Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression.

Journal: Blood advances

Published: August 13, 2025

Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.

Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 03, 2025

Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4.

Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4.

Journal: Blood cancer journal

Published: April 02, 2025

CAR-T cell therapy in Multiple Myeloma: current status and future challenges.

CAR-T cell therapy in Multiple Myeloma: current status and future challenges.

Journal: Blood cancer journal

Published: September 02, 2024

Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.

Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.

Journal: Future oncology (London, England)

Published: July 27, 2023

Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.

Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.

Journal: Future oncology (London, England)

Published: July 05, 2023

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.

Journal: Journal for immunotherapy of cancer

Published: March 30, 2023

Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.

Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: March 21, 2023

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.

Journal: Nature medicine

Published: July 28, 2022

Showing 1-12 of 58

Last Updated: 09/26/2026